
CANF Stock Forecast & Price Target
CANF Analyst Ratings
Bulls say
Can Fite Biopharma's positive outlook is bolstered by its strong pipeline of drug candidates, with risk-adjusted sales projections for Namodenoson and Piclidenoson showing substantial growth, from approximately $3 million in 2027 to $126 million by 2031. The company is positioning its drugs for initial market entry at the end of 2027, with a projected peak market penetration of 5%, indicating optimism around potential market acceptance and competitive positioning. Additionally, compelling clinical results, including a significant complete response in a patient with advanced liver cancer treated with Namodenoson, enhance the prospects for securing FDA and EMA approvals, affirming the potential for successful commercialization of its therapies.
Bears say
Can Fite Biopharma Ltd is facing significant challenges that contribute to a negative outlook on its stock. The company's inability to successfully commercialize its drug products or achieve the expected market penetration could severely impact revenue forecasts, while potential delays in regulatory approvals may hinder its financial performance further. Additionally, the projection of increasing net losses, along with anticipated dilution and heightened competitive pressures, raises concerns about the company's future viability and its ability to protect intellectual property rights.
This aggregate rating is based on analysts' research of Can-Fite BioPharma Ltd. and is not a guaranteed prediction by Public.com or investment advice.
CANF Analyst Forecast & Price Prediction
Start investing in CANF
Order type
Buy in
Order amount
Est. shares
0 shares